| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Neoplasms | 201 | 2022 | 4849 | 8.240 |
Why?
|
| Glioma | 89 | 2022 | 1963 | 4.430 |
Why?
|
| Neurosurgical Procedures | 23 | 2021 | 609 | 4.010 |
Why?
|
| Glioblastoma | 72 | 2022 | 1797 | 3.870 |
Why?
|
| Cerebral Ventricle Neoplasms | 8 | 2023 | 81 | 2.420 |
Why?
|
| Craniotomy | 17 | 2014 | 304 | 1.730 |
Why?
|
| Neurosurgery | 10 | 2015 | 108 | 1.660 |
Why?
|
| Radiosurgery | 27 | 2018 | 1330 | 1.660 |
Why?
|
| Magnetic Resonance Imaging | 50 | 2023 | 7702 | 1.420 |
Why?
|
| Meningeal Neoplasms | 14 | 2009 | 441 | 1.300 |
Why?
|
| Glioma, Subependymal | 3 | 2023 | 25 | 1.270 |
Why?
|
| Astrocytoma | 18 | 2014 | 321 | 1.110 |
Why?
|
| Meningioma | 17 | 2010 | 289 | 1.010 |
Why?
|
| Postoperative Complications | 21 | 2017 | 5542 | 0.910 |
Why?
|
| Brain Diseases | 6 | 2009 | 403 | 0.880 |
Why?
|
| Collagenases | 9 | 1998 | 74 | 0.810 |
Why?
|
| Stereotaxic Techniques | 13 | 2010 | 172 | 0.800 |
Why?
|
| Humans | 307 | 2023 | 261506 | 0.800 |
Why?
|
| Middle Aged | 124 | 2023 | 86204 | 0.750 |
Why?
|
| Lateral Ventricles | 2 | 2010 | 26 | 0.700 |
Why?
|
| Third Ventricle | 3 | 2010 | 37 | 0.660 |
Why?
|
| Medical Oncology | 10 | 2020 | 1423 | 0.650 |
Why?
|
| Cysts | 6 | 2005 | 197 | 0.650 |
Why?
|
| Adult | 110 | 2022 | 77950 | 0.650 |
Why?
|
| Karnofsky Performance Status | 13 | 2015 | 175 | 0.620 |
Why?
|
| Male | 131 | 2023 | 123000 | 0.610 |
Why?
|
| Tyrphostins | 5 | 2022 | 107 | 0.610 |
Why?
|
| Female | 134 | 2023 | 141928 | 0.590 |
Why?
|
| Brain | 31 | 2018 | 4113 | 0.590 |
Why?
|
| Metalloendopeptidases | 13 | 1998 | 170 | 0.590 |
Why?
|
| Carmustine | 5 | 2002 | 214 | 0.570 |
Why?
|
| Cerebral Ventricles | 2 | 2010 | 98 | 0.570 |
Why?
|
| Preoperative Care | 5 | 2016 | 1529 | 0.560 |
Why?
|
| Retrospective Studies | 48 | 2023 | 37905 | 0.560 |
Why?
|
| Aged | 88 | 2020 | 70117 | 0.550 |
Why?
|
| Cranial Irradiation | 10 | 2009 | 315 | 0.550 |
Why?
|
| Fourth Ventricle | 4 | 2023 | 51 | 0.540 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 6 | 1995 | 65 | 0.540 |
Why?
|
| Neoplasm Recurrence, Local | 23 | 2023 | 10035 | 0.520 |
Why?
|
| Forkhead Transcription Factors | 8 | 2014 | 778 | 0.520 |
Why?
|
| Gelatinases | 10 | 1998 | 52 | 0.520 |
Why?
|
| Antineoplastic Agents, Alkylating | 8 | 2010 | 588 | 0.520 |
Why?
|
| Motor Cortex | 3 | 2010 | 117 | 0.510 |
Why?
|
| Survival Rate | 38 | 2018 | 12221 | 0.510 |
Why?
|
| Young Adult | 28 | 2022 | 21445 | 0.500 |
Why?
|
| STAT3 Transcription Factor | 13 | 2022 | 1121 | 0.480 |
Why?
|
| Treatment Outcome | 42 | 2022 | 32848 | 0.470 |
Why?
|
| Monitoring, Intraoperative | 7 | 2014 | 264 | 0.460 |
Why?
|
| Neoplasm Invasiveness | 35 | 2014 | 3981 | 0.450 |
Why?
|
| Adolescent | 44 | 2022 | 31252 | 0.440 |
Why?
|
| Survival Analysis | 23 | 2015 | 9180 | 0.430 |
Why?
|
| Plasminogen Activators | 9 | 2000 | 52 | 0.420 |
Why?
|
| Brain Damage, Chronic | 3 | 2004 | 37 | 0.420 |
Why?
|
| Choroid Plexus | 2 | 2002 | 31 | 0.420 |
Why?
|
| Neuronavigation | 4 | 2016 | 47 | 0.420 |
Why?
|
| Supratentorial Neoplasms | 3 | 2013 | 78 | 0.420 |
Why?
|
| Hospitals, University | 3 | 2020 | 209 | 0.410 |
Why?
|
| Urokinase-Type Plasminogen Activator | 12 | 1999 | 136 | 0.410 |
Why?
|
| Thromboembolism | 5 | 1994 | 155 | 0.400 |
Why?
|
| Tissue Plasminogen Activator | 6 | 1998 | 163 | 0.390 |
Why?
|
| Pyridines | 5 | 2022 | 1244 | 0.380 |
Why?
|
| Receptors, Cell Surface | 14 | 2000 | 862 | 0.370 |
Why?
|
| Neoplasm Metastasis | 12 | 2018 | 5112 | 0.370 |
Why?
|
| Aged, 80 and over | 35 | 2020 | 29902 | 0.370 |
Why?
|
| Spinal Cord | 4 | 1994 | 690 | 0.370 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 3 | 2013 | 341 | 0.360 |
Why?
|
| Brain Mapping | 10 | 2017 | 644 | 0.360 |
Why?
|
| Prognosis | 33 | 2018 | 21713 | 0.360 |
Why?
|
| T-Lymphocytes, Regulatory | 5 | 2010 | 673 | 0.360 |
Why?
|
| Combined Modality Therapy | 23 | 2010 | 8865 | 0.350 |
Why?
|
| Cerebral Cortex | 6 | 2013 | 621 | 0.350 |
Why?
|
| Clinical Clerkship | 1 | 2010 | 87 | 0.350 |
Why?
|
| Corpus Callosum | 1 | 2010 | 138 | 0.350 |
Why?
|
| Internship and Residency | 3 | 2012 | 1375 | 0.350 |
Why?
|
| Schools, Medical | 1 | 2010 | 132 | 0.340 |
Why?
|
| Matrix Metalloproteinase 2 | 15 | 2007 | 256 | 0.340 |
Why?
|
| Autophagy | 8 | 2008 | 927 | 0.340 |
Why?
|
| Astrocytes | 8 | 2010 | 368 | 0.340 |
Why?
|
| Patient Selection | 7 | 2014 | 2055 | 0.340 |
Why?
|
| Cerebellopontine Angle | 1 | 2008 | 12 | 0.330 |
Why?
|
| Oncolytic Virotherapy | 3 | 2019 | 280 | 0.330 |
Why?
|
| Decision Support Techniques | 1 | 2014 | 622 | 0.330 |
Why?
|
| Wakefulness | 4 | 2014 | 150 | 0.330 |
Why?
|
| Mice, Nude | 28 | 2018 | 4307 | 0.320 |
Why?
|
| Neoplasm, Residual | 5 | 2015 | 1656 | 0.320 |
Why?
|
| O(6)-Methylguanine-DNA Methyltransferase | 3 | 2010 | 69 | 0.320 |
Why?
|
| Gene Expression Regulation, Neoplastic | 19 | 2015 | 8873 | 0.300 |
Why?
|
| Fibrinolysis | 5 | 1994 | 63 | 0.300 |
Why?
|
| Radiotherapy | 5 | 2010 | 1824 | 0.290 |
Why?
|
| ErbB Receptors | 7 | 2012 | 2295 | 0.290 |
Why?
|
| Dura Mater | 3 | 2001 | 73 | 0.290 |
Why?
|
| Incidence | 8 | 2015 | 5673 | 0.290 |
Why?
|
| Adenoviridae | 10 | 2018 | 1459 | 0.280 |
Why?
|
| Surgery, Computer-Assisted | 3 | 2014 | 255 | 0.280 |
Why?
|
| Apoptosis | 15 | 2018 | 7591 | 0.280 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 18 | 2010 | 1489 | 0.270 |
Why?
|
| Choroid Plexus Neoplasms | 2 | 2006 | 26 | 0.270 |
Why?
|
| Pineal Gland | 1 | 2005 | 50 | 0.270 |
Why?
|
| Speech | 2 | 2017 | 133 | 0.260 |
Why?
|
| Intraoperative Neurophysiological Monitoring | 2 | 2016 | 32 | 0.260 |
Why?
|
| Neovascularization, Pathologic | 8 | 2015 | 1547 | 0.260 |
Why?
|
| Necrosis | 10 | 2008 | 580 | 0.260 |
Why?
|
| Neoplasm Proteins | 10 | 2014 | 3230 | 0.260 |
Why?
|
| Matrix Metalloproteinase 9 | 11 | 2005 | 360 | 0.250 |
Why?
|
| Spinal Cord Diseases | 4 | 1994 | 90 | 0.250 |
Why?
|
| Follow-Up Studies | 18 | 2017 | 14889 | 0.250 |
Why?
|
| Cohort Studies | 13 | 2017 | 9244 | 0.250 |
Why?
|
| Cell Line, Tumor | 33 | 2020 | 14551 | 0.250 |
Why?
|
| Databases as Topic | 1 | 2005 | 133 | 0.250 |
Why?
|
| Microsurgery | 4 | 2004 | 244 | 0.240 |
Why?
|
| Kaplan-Meier Estimate | 7 | 2020 | 6207 | 0.240 |
Why?
|
| Isocitrate Dehydrogenase | 4 | 2020 | 480 | 0.240 |
Why?
|
| Blotting, Western | 20 | 2010 | 3536 | 0.230 |
Why?
|
| Radiotherapy, Adjuvant | 11 | 2017 | 2231 | 0.230 |
Why?
|
| Anesthesia, Epidural | 2 | 1994 | 31 | 0.230 |
Why?
|
| Oligodendroglioma | 4 | 2006 | 106 | 0.230 |
Why?
|
| Sarcoma | 7 | 2014 | 1725 | 0.230 |
Why?
|
| Kidney Neoplasms | 8 | 2008 | 3022 | 0.230 |
Why?
|
| Neoplastic Stem Cells | 6 | 2014 | 1443 | 0.230 |
Why?
|
| Diagnosis, Differential | 13 | 2014 | 4744 | 0.230 |
Why?
|
| Prospective Studies | 16 | 2021 | 12873 | 0.230 |
Why?
|
| Lung Neoplasms | 19 | 2017 | 11538 | 0.230 |
Why?
|
| Child, Preschool | 9 | 2015 | 16273 | 0.230 |
Why?
|
| Melanoma | 12 | 2008 | 5317 | 0.220 |
Why?
|
| Skull Neoplasms | 3 | 2001 | 67 | 0.220 |
Why?
|
| Hemangiopericytoma | 2 | 2002 | 56 | 0.220 |
Why?
|
| Mice | 43 | 2020 | 34495 | 0.220 |
Why?
|
| Tomography, X-Ray Computed | 14 | 2010 | 7551 | 0.220 |
Why?
|
| Carcinoid Tumor | 1 | 2004 | 280 | 0.210 |
Why?
|
| Genetic Therapy | 7 | 2008 | 1616 | 0.210 |
Why?
|
| Animals | 55 | 2020 | 59536 | 0.210 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 1 | 2005 | 184 | 0.210 |
Why?
|
| Genes, Neoplasm | 1 | 2004 | 324 | 0.210 |
Why?
|
| Skull | 2 | 2010 | 231 | 0.210 |
Why?
|
| Image Processing, Computer-Assisted | 5 | 2018 | 1648 | 0.210 |
Why?
|
| Immunohistochemistry | 26 | 2014 | 7548 | 0.210 |
Why?
|
| Predictive Value of Tests | 8 | 2014 | 4892 | 0.210 |
Why?
|
| Pinealoma | 1 | 2022 | 49 | 0.200 |
Why?
|
| Carcinoma, Renal Cell | 5 | 2008 | 2326 | 0.200 |
Why?
|
| Electric Stimulation | 4 | 2016 | 426 | 0.200 |
Why?
|
| Language | 2 | 2017 | 309 | 0.200 |
Why?
|
| Crowdsourcing | 1 | 2021 | 21 | 0.200 |
Why?
|
| Multivariate Analysis | 7 | 2014 | 4298 | 0.200 |
Why?
|
| Child | 16 | 2017 | 29154 | 0.200 |
Why?
|
| MicroRNAs | 4 | 2018 | 2947 | 0.200 |
Why?
|
| Disease Progression | 20 | 2022 | 6682 | 0.200 |
Why?
|
| Breast Neoplasms | 15 | 2020 | 15694 | 0.200 |
Why?
|
| Neuroglia | 4 | 2010 | 223 | 0.200 |
Why?
|
| Osteosarcoma | 3 | 2010 | 929 | 0.200 |
Why?
|
| Tumor Cells, Cultured | 27 | 2018 | 5395 | 0.200 |
Why?
|
| Soft Tissue Neoplasms | 3 | 2000 | 882 | 0.190 |
Why?
|
| Carcinoma, Endometrioid | 1 | 2004 | 323 | 0.190 |
Why?
|
| Fibronectins | 4 | 1996 | 197 | 0.190 |
Why?
|
| STAT5 Transcription Factor | 2 | 2012 | 214 | 0.190 |
Why?
|
| Biomarkers, Tumor | 9 | 2018 | 10331 | 0.190 |
Why?
|
| Microtubule-Associated Proteins | 4 | 2013 | 534 | 0.190 |
Why?
|
| Reoperation | 8 | 2005 | 1382 | 0.180 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2004 | 436 | 0.180 |
Why?
|
| Nevus of Ota | 1 | 1999 | 2 | 0.180 |
Why?
|
| DNA Methylation | 5 | 2015 | 2669 | 0.180 |
Why?
|
| Carcinoma, Papillary | 1 | 2004 | 584 | 0.180 |
Why?
|
| Immune Tolerance | 3 | 2010 | 403 | 0.180 |
Why?
|
| Occipital Lobe | 1 | 1999 | 48 | 0.180 |
Why?
|
| Texas | 5 | 2020 | 6311 | 0.180 |
Why?
|
| Aminocaproic Acid | 4 | 1994 | 17 | 0.180 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2004 | 486 | 0.180 |
Why?
|
| Risk Factors | 9 | 2014 | 17523 | 0.170 |
Why?
|
| Nervous System Diseases | 5 | 2017 | 500 | 0.170 |
Why?
|
| Viral Matrix Proteins | 1 | 2020 | 201 | 0.170 |
Why?
|
| Spinal Neoplasms | 3 | 1998 | 631 | 0.170 |
Why?
|
| Recovery of Function | 2 | 2015 | 703 | 0.170 |
Why?
|
| Hydrocephalus | 4 | 2005 | 217 | 0.170 |
Why?
|
| Collagen | 10 | 2000 | 752 | 0.170 |
Why?
|
| Neuropsychological Tests | 1 | 2003 | 1178 | 0.160 |
Why?
|
| Cell Adhesion Molecules | 4 | 2018 | 577 | 0.160 |
Why?
|
| Mutation | 11 | 2021 | 15179 | 0.160 |
Why?
|
| Cerebral Hemorrhage | 1 | 1999 | 183 | 0.160 |
Why?
|
| Transplantation, Heterologous | 9 | 2013 | 1082 | 0.160 |
Why?
|
| Gene Expression Profiling | 5 | 2015 | 5159 | 0.160 |
Why?
|
| Forkhead Box Protein M1 | 7 | 2014 | 113 | 0.160 |
Why?
|
| Clinical Competence | 1 | 2006 | 1270 | 0.160 |
Why?
|
| Cytomegalovirus Infections | 2 | 2020 | 462 | 0.160 |
Why?
|
| Time Factors | 13 | 2017 | 12926 | 0.160 |
Why?
|
| Wernicke Area | 1 | 2017 | 11 | 0.160 |
Why?
|
| Cerebral Angiography | 4 | 2010 | 129 | 0.160 |
Why?
|
| Skull Base Neoplasms | 2 | 2010 | 314 | 0.160 |
Why?
|
| Blotting, Northern | 12 | 2005 | 682 | 0.150 |
Why?
|
| Thoracic Vertebrae | 1 | 1998 | 186 | 0.150 |
Why?
|
| Eyelid Neoplasms | 1 | 1999 | 191 | 0.150 |
Why?
|
| RNA, Messenger | 16 | 2006 | 6150 | 0.150 |
Why?
|
| Dacarbazine | 5 | 2010 | 485 | 0.150 |
Why?
|
| Electrodiagnosis | 2 | 1994 | 19 | 0.150 |
Why?
|
| Oncolytic Viruses | 2 | 2018 | 204 | 0.150 |
Why?
|
| DNA-Binding Proteins | 5 | 2012 | 4821 | 0.150 |
Why?
|
| Signal Transduction | 12 | 2014 | 11965 | 0.150 |
Why?
|
| Stroke | 1 | 2005 | 1144 | 0.150 |
Why?
|
| Hemostasis, Surgical | 2 | 1987 | 48 | 0.140 |
Why?
|
| Arachnoid | 3 | 2008 | 13 | 0.140 |
Why?
|
| Molecular Imaging | 1 | 2018 | 185 | 0.140 |
Why?
|
| Magnetic Resonance Spectroscopy | 3 | 2004 | 624 | 0.140 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 1 | 2018 | 204 | 0.140 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 5 | 2008 | 2508 | 0.140 |
Why?
|
| Clinical Trials as Topic | 6 | 2010 | 3719 | 0.140 |
Why?
|
| Neoplasm Transplantation | 8 | 2014 | 1519 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-akt | 5 | 2007 | 2054 | 0.140 |
Why?
|
| Cell Movement | 8 | 2011 | 2466 | 0.140 |
Why?
|
| Gene Expression | 4 | 2018 | 3570 | 0.140 |
Why?
|
| Evoked Potentials | 2 | 1994 | 190 | 0.140 |
Why?
|
| Data Collection | 2 | 2010 | 620 | 0.130 |
Why?
|
| Carrier Proteins | 3 | 2010 | 2022 | 0.130 |
Why?
|
| Hemostasis | 2 | 1994 | 109 | 0.130 |
Why?
|
| Bone Neoplasms | 6 | 2003 | 2576 | 0.130 |
Why?
|
| Vascular Endothelial Growth Factor A | 7 | 2008 | 1533 | 0.130 |
Why?
|
| Aminocaproates | 2 | 1986 | 2 | 0.130 |
Why?
|
| SOXB1 Transcription Factors | 1 | 2015 | 123 | 0.130 |
Why?
|
| Molecular Weight | 6 | 1998 | 629 | 0.130 |
Why?
|
| Watchful Waiting | 1 | 2017 | 289 | 0.130 |
Why?
|
| Exosomes | 1 | 2018 | 253 | 0.130 |
Why?
|
| Iodine Radioisotopes | 2 | 1994 | 371 | 0.130 |
Why?
|
| Intraoperative Care | 1 | 2016 | 259 | 0.130 |
Why?
|
| Brain Chemistry | 4 | 1996 | 145 | 0.130 |
Why?
|
| RNA, Neoplasm | 7 | 2013 | 771 | 0.120 |
Why?
|
| Plasmacytoma | 1 | 1995 | 111 | 0.120 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 7 | 1998 | 568 | 0.120 |
Why?
|
| Transfection | 13 | 2010 | 2944 | 0.120 |
Why?
|
| Mice, Inbred BALB C | 9 | 2015 | 2314 | 0.120 |
Why?
|
| Pia Mater | 2 | 2008 | 14 | 0.120 |
Why?
|
| Molecular Sequence Data | 11 | 2013 | 6089 | 0.120 |
Why?
|
| Cell Communication | 3 | 2015 | 509 | 0.120 |
Why?
|
| Radiation Injuries, Experimental | 1 | 1994 | 82 | 0.120 |
Why?
|
| Histones | 1 | 2021 | 1466 | 0.120 |
Why?
|
| Dominance, Cerebral | 1 | 2004 | 81 | 0.120 |
Why?
|
| Pyramidal Tracts | 1 | 2014 | 57 | 0.120 |
Why?
|
| Immunosuppressive Agents | 1 | 2020 | 1375 | 0.120 |
Why?
|
| Brachytherapy | 3 | 2002 | 977 | 0.120 |
Why?
|
| Ohio | 1 | 2014 | 113 | 0.120 |
Why?
|
| Atlases as Topic | 1 | 2014 | 42 | 0.120 |
Why?
|
| Fibrinolysin | 3 | 1994 | 33 | 0.120 |
Why?
|
| Nonlinear Dynamics | 1 | 2014 | 78 | 0.120 |
Why?
|
| Antineoplastic Agents | 12 | 2014 | 14289 | 0.120 |
Why?
|
| Promoter Regions, Genetic | 7 | 2015 | 3101 | 0.120 |
Why?
|
| Cytomegalovirus | 2 | 2020 | 482 | 0.120 |
Why?
|
| Cancer Vaccines | 2 | 2010 | 697 | 0.120 |
Why?
|
| Angiofibroma | 1 | 2003 | 17 | 0.110 |
Why?
|
| Gene Transfer Techniques | 4 | 2000 | 716 | 0.110 |
Why?
|
| Rats | 11 | 2006 | 6086 | 0.110 |
Why?
|
| Serpins | 1 | 1993 | 77 | 0.110 |
Why?
|
| Parietal Lobe | 1 | 1993 | 66 | 0.110 |
Why?
|
| Cytoskeleton | 3 | 1999 | 267 | 0.110 |
Why?
|
| Neoplasms | 13 | 2014 | 15193 | 0.110 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2000 | 1248 | 0.110 |
Why?
|
| Biomedical Research | 3 | 2009 | 806 | 0.110 |
Why?
|
| Smad3 Protein | 1 | 2014 | 129 | 0.110 |
Why?
|
| Laminin | 7 | 2000 | 194 | 0.110 |
Why?
|
| Heat-Shock Response | 1 | 2012 | 40 | 0.110 |
Why?
|
| Software | 3 | 2014 | 1321 | 0.110 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2013 | 62 | 0.110 |
Why?
|
| Cells, Cultured | 9 | 2020 | 5637 | 0.110 |
Why?
|
| Vaccines, Subunit | 2 | 2010 | 124 | 0.110 |
Why?
|
| Tumor Suppressor Protein p53 | 4 | 2009 | 3552 | 0.110 |
Why?
|
| Phenytoin | 1 | 2013 | 71 | 0.110 |
Why?
|
| Neuroimaging | 1 | 2016 | 403 | 0.110 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2014 | 566 | 0.110 |
Why?
|
| Neuroectodermal Tumors, Primitive, Peripheral | 1 | 2002 | 36 | 0.110 |
Why?
|
| DNA, Antisense | 4 | 2000 | 42 | 0.110 |
Why?
|
| Phosphotyrosine | 2 | 2011 | 111 | 0.110 |
Why?
|
| Neurocytoma | 1 | 2002 | 17 | 0.110 |
Why?
|
| Smad4 Protein | 1 | 2014 | 196 | 0.110 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2009 | 476 | 0.110 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2020 | 1586 | 0.110 |
Why?
|
| Carcinoma | 2 | 2003 | 2578 | 0.110 |
Why?
|
| Image Interpretation, Computer-Assisted | 4 | 2018 | 592 | 0.110 |
Why?
|
| Radiography | 6 | 2022 | 1904 | 0.110 |
Why?
|
| bcl-X Protein | 1 | 2012 | 196 | 0.100 |
Why?
|
| Intraoperative Complications | 1 | 2014 | 301 | 0.100 |
Why?
|
| Proportional Hazards Models | 5 | 2020 | 4988 | 0.100 |
Why?
|
| Receptors, Urokinase Plasminogen Activator | 11 | 2000 | 107 | 0.100 |
Why?
|
| Osteolysis | 1 | 1992 | 80 | 0.100 |
Why?
|
| Radiation Protection | 1 | 1993 | 205 | 0.100 |
Why?
|
| Radiation-Sensitizing Agents | 2 | 2007 | 363 | 0.100 |
Why?
|
| Plasminogen | 3 | 2000 | 26 | 0.100 |
Why?
|
| Gene Fusion | 1 | 2013 | 209 | 0.100 |
Why?
|
| Cell Transformation, Neoplastic | 4 | 2011 | 2359 | 0.100 |
Why?
|
| Logistic Models | 4 | 2016 | 3441 | 0.100 |
Why?
|
| Postoperative Care | 2 | 2017 | 739 | 0.100 |
Why?
|
| Antibodies | 4 | 2008 | 838 | 0.100 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2014 | 565 | 0.100 |
Why?
|
| Postoperative Period | 3 | 2018 | 665 | 0.100 |
Why?
|
| Dalteparin | 1 | 2010 | 13 | 0.100 |
Why?
|
| Proteomics | 2 | 2008 | 1380 | 0.100 |
Why?
|
| Endarterectomy | 2 | 1981 | 25 | 0.100 |
Why?
|
| Radiation Injuries | 3 | 2004 | 1411 | 0.090 |
Why?
|
| Phosphorylation | 8 | 2012 | 4804 | 0.090 |
Why?
|
| Endothelium, Vascular | 3 | 2000 | 891 | 0.090 |
Why?
|
| Nasopharyngeal Neoplasms | 1 | 2003 | 323 | 0.090 |
Why?
|
| Cell Hypoxia | 2 | 2002 | 328 | 0.090 |
Why?
|
| Neoplasms, Radiation-Induced | 2 | 2010 | 388 | 0.090 |
Why?
|
| Brain Stem Neoplasms | 1 | 2011 | 108 | 0.090 |
Why?
|
| Flow Cytometry | 7 | 2014 | 3033 | 0.090 |
Why?
|
| Oligonucleotides, Antisense | 3 | 2005 | 248 | 0.090 |
Why?
|
| Perceptual Disorders | 1 | 2010 | 14 | 0.090 |
Why?
|
| Biopsy | 5 | 2018 | 3443 | 0.090 |
Why?
|
| Intracranial Hemorrhages | 1 | 2011 | 121 | 0.090 |
Why?
|
| Aphasia | 1 | 2010 | 21 | 0.090 |
Why?
|
| Protein Biosynthesis | 3 | 2001 | 889 | 0.090 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2020 | 1763 | 0.090 |
Why?
|
| Endosomal Sorting Complexes Required for Transport | 1 | 2010 | 60 | 0.090 |
Why?
|
| Image Enhancement | 1 | 2004 | 561 | 0.090 |
Why?
|
| Skin Neoplasms | 5 | 2006 | 4654 | 0.090 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2010 | 66 | 0.090 |
Why?
|
| Spinal Cord Neoplasms | 1 | 1991 | 142 | 0.090 |
Why?
|
| Rats, Inbred F344 | 3 | 1994 | 224 | 0.090 |
Why?
|
| Serine | 2 | 2009 | 388 | 0.090 |
Why?
|
| Reproducibility of Results | 4 | 2014 | 6009 | 0.090 |
Why?
|
| Genomics | 2 | 2018 | 2738 | 0.090 |
Why?
|
| Esophageal Neoplasms | 1 | 2003 | 3168 | 0.090 |
Why?
|
| Cranial Nerve Injuries | 2 | 2017 | 9 | 0.090 |
Why?
|
| Macrophages | 2 | 2020 | 1304 | 0.090 |
Why?
|
| Oxygen | 1 | 2004 | 754 | 0.090 |
Why?
|
| Cancer Care Facilities | 1 | 2014 | 884 | 0.090 |
Why?
|
| Seizures | 2 | 2013 | 989 | 0.090 |
Why?
|
| Cerebellar Neoplasms | 4 | 2008 | 434 | 0.090 |
Why?
|
| Wnt Proteins | 1 | 2011 | 397 | 0.090 |
Why?
|
| Integrins | 3 | 2003 | 262 | 0.090 |
Why?
|
| Sequence Analysis, RNA | 1 | 2013 | 651 | 0.090 |
Why?
|
| Cell Adhesion | 5 | 2006 | 1008 | 0.090 |
Why?
|
| Anticonvulsants | 1 | 2013 | 431 | 0.090 |
Why?
|
| Receptors, Progesterone | 1 | 2015 | 1392 | 0.090 |
Why?
|
| Phosphoproteins | 4 | 2010 | 1152 | 0.090 |
Why?
|
| Societies, Medical | 3 | 2010 | 1335 | 0.090 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 2 | 1 | 2009 | 89 | 0.090 |
Why?
|
| Radium | 1 | 2010 | 93 | 0.090 |
Why?
|
| Brain Edema | 3 | 1992 | 86 | 0.090 |
Why?
|
| Base Sequence | 9 | 2013 | 4917 | 0.090 |
Why?
|
| Matrix Metalloproteinase Inhibitors | 3 | 2000 | 57 | 0.080 |
Why?
|
| Neoplasms, Second Primary | 2 | 2010 | 1350 | 0.080 |
Why?
|
| Disease-Free Survival | 9 | 2017 | 10001 | 0.080 |
Why?
|
| Microglia | 1 | 2010 | 164 | 0.080 |
Why?
|
| Endothelial Cells | 1 | 2015 | 1048 | 0.080 |
Why?
|
| Bone Screws | 2 | 2000 | 84 | 0.080 |
Why?
|
| Suppressor of Cytokine Signaling Proteins | 1 | 2008 | 60 | 0.080 |
Why?
|
| Morbidity | 1 | 2010 | 397 | 0.080 |
Why?
|
| Genetic Vectors | 5 | 2008 | 1694 | 0.080 |
Why?
|
| Mice, Inbred C57BL | 5 | 2020 | 6942 | 0.080 |
Why?
|
| Perioperative Care | 1 | 2013 | 451 | 0.080 |
Why?
|
| Referral and Consultation | 1 | 2014 | 899 | 0.080 |
Why?
|
| Lymphopenia | 1 | 2010 | 199 | 0.080 |
Why?
|
| Thromboplastin | 1 | 2008 | 34 | 0.080 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2003 | 2488 | 0.080 |
Why?
|
| Hyalin | 1 | 1988 | 17 | 0.080 |
Why?
|
| Disseminated Intravascular Coagulation | 2 | 1992 | 106 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 3 | 2006 | 1493 | 0.080 |
Why?
|
| Cell Survival | 6 | 2012 | 3045 | 0.080 |
Why?
|
| Genes, Tumor Suppressor | 2 | 2006 | 1064 | 0.080 |
Why?
|
| Oligonucleotides | 2 | 2007 | 227 | 0.080 |
Why?
|
| Pulmonary Embolism | 2 | 1998 | 329 | 0.080 |
Why?
|
| alpha 1-Antitrypsin | 2 | 1987 | 97 | 0.080 |
Why?
|
| Accessory Nerve Injuries | 1 | 1987 | 1 | 0.080 |
Why?
|
| Epigenesis, Genetic | 1 | 2015 | 1399 | 0.080 |
Why?
|
| Transforming Growth Factor beta | 1 | 2014 | 1130 | 0.080 |
Why?
|
| Mentors | 1 | 2010 | 203 | 0.080 |
Why?
|
| Trans-Activators | 2 | 2005 | 1555 | 0.080 |
Why?
|
| Threonine | 1 | 2008 | 161 | 0.080 |
Why?
|
| Inositol | 1 | 2007 | 27 | 0.080 |
Why?
|
| Ubiquitin-Protein Ligases | 2 | 2010 | 854 | 0.080 |
Why?
|
| Ovarian Neoplasms | 1 | 2004 | 4638 | 0.080 |
Why?
|
| Neoplasm Seeding | 1 | 2008 | 66 | 0.080 |
Why?
|
| Central Nervous System Neoplasms | 4 | 2008 | 502 | 0.080 |
Why?
|
| Mitosis | 1 | 2010 | 615 | 0.080 |
Why?
|
| Neoplasm Grading | 3 | 2020 | 1742 | 0.080 |
Why?
|
| beta Catenin | 1 | 2011 | 688 | 0.080 |
Why?
|
| Neuroma, Acoustic | 4 | 1991 | 55 | 0.080 |
Why?
|
| T-Lymphocytes | 5 | 2014 | 3869 | 0.080 |
Why?
|
| Medulloblastoma | 3 | 2005 | 540 | 0.080 |
Why?
|
| Receptors, Estrogen | 1 | 2015 | 2086 | 0.080 |
Why?
|
| Transcription Factors | 3 | 2014 | 5270 | 0.080 |
Why?
|
| Cost-Benefit Analysis | 2 | 2004 | 945 | 0.080 |
Why?
|
| Infant | 3 | 2014 | 13310 | 0.080 |
Why?
|
| p21-Activated Kinases | 1 | 2007 | 122 | 0.080 |
Why?
|
| Robotics | 2 | 2005 | 359 | 0.070 |
Why?
|
| Faculty, Medical | 1 | 2010 | 289 | 0.070 |
Why?
|
| Sirolimus | 3 | 2008 | 814 | 0.070 |
Why?
|
| Plasma Cells | 1 | 1988 | 192 | 0.070 |
Why?
|
| Odds Ratio | 2 | 2010 | 2316 | 0.070 |
Why?
|
| Xenograft Model Antitumor Assays | 4 | 2018 | 3821 | 0.070 |
Why?
|
| Monocytes | 1 | 2011 | 788 | 0.070 |
Why?
|
| Tumor Burden | 3 | 2022 | 1987 | 0.070 |
Why?
|
| ras Proteins | 2 | 2002 | 770 | 0.070 |
Why?
|
| Risk | 3 | 2016 | 1972 | 0.070 |
Why?
|
| Neoplasm Staging | 6 | 2006 | 13658 | 0.070 |
Why?
|
| Age Factors | 5 | 2004 | 5377 | 0.070 |
Why?
|
| Sleep | 1 | 1989 | 413 | 0.070 |
Why?
|
| Granuloma | 1 | 1988 | 154 | 0.070 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2009 | 709 | 0.070 |
Why?
|
| Registries | 1 | 2014 | 2170 | 0.070 |
Why?
|
| Up-Regulation | 3 | 2014 | 2450 | 0.070 |
Why?
|
| Curriculum | 1 | 2012 | 860 | 0.070 |
Why?
|
| Curcumin | 1 | 2007 | 117 | 0.070 |
Why?
|
| Cell Division | 4 | 2007 | 2489 | 0.070 |
Why?
|
| Telomerase | 2 | 2007 | 525 | 0.070 |
Why?
|
| Cerebrovascular Circulation | 1 | 1989 | 471 | 0.070 |
Why?
|
| Injections, Intralesional | 3 | 2018 | 164 | 0.070 |
Why?
|
| Cathepsins | 2 | 1996 | 46 | 0.070 |
Why?
|
| Blood Coagulation Tests | 3 | 1992 | 87 | 0.070 |
Why?
|
| Precision Medicine | 1 | 2014 | 1154 | 0.070 |
Why?
|
| Specialty Boards | 1 | 2006 | 46 | 0.070 |
Why?
|
| Neuroendoscopes | 1 | 2005 | 3 | 0.070 |
Why?
|
| Actins | 2 | 1999 | 608 | 0.070 |
Why?
|
| Education, Medical, Graduate | 1 | 2012 | 671 | 0.070 |
Why?
|
| Cell Culture Techniques | 1 | 2009 | 598 | 0.070 |
Why?
|
| Thrombocytopenia | 1 | 2011 | 846 | 0.070 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2002 | 1538 | 0.070 |
Why?
|
| Enzyme Inhibitors | 4 | 2007 | 1879 | 0.070 |
Why?
|
| Deoxyribonucleases | 1 | 2005 | 46 | 0.070 |
Why?
|
| Age Distribution | 3 | 2017 | 698 | 0.070 |
Why?
|
| Immunotherapy | 2 | 2010 | 3341 | 0.070 |
Why?
|
| Disease Susceptibility | 3 | 1992 | 538 | 0.070 |
Why?
|
| NF-kappa B | 3 | 2008 | 1549 | 0.070 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2003 | 15862 | 0.070 |
Why?
|
| North America | 1 | 2006 | 314 | 0.070 |
Why?
|
| Proteoglycans | 5 | 2000 | 259 | 0.070 |
Why?
|
| Transcription, Genetic | 3 | 2008 | 3154 | 0.070 |
Why?
|
| Fatal Outcome | 2 | 2002 | 829 | 0.070 |
Why?
|
| Cytosine Deaminase | 1 | 2005 | 39 | 0.070 |
Why?
|
| Severity of Illness Index | 3 | 2010 | 4320 | 0.070 |
Why?
|
| Receptor, ErbB-2 | 1 | 2015 | 2518 | 0.060 |
Why?
|
| Neurons | 3 | 2006 | 2287 | 0.060 |
Why?
|
| Preoperative Period | 2 | 2017 | 344 | 0.060 |
Why?
|
| United States | 6 | 2017 | 15433 | 0.060 |
Why?
|
| Sella Turcica | 1 | 1984 | 24 | 0.060 |
Why?
|
| Ultrasonography, Interventional | 2 | 2001 | 429 | 0.060 |
Why?
|
| Radiation Tolerance | 2 | 2005 | 629 | 0.060 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2007 | 460 | 0.060 |
Why?
|
| Students, Medical | 1 | 2010 | 399 | 0.060 |
Why?
|
| Headache | 1 | 2005 | 163 | 0.060 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2006 | 301 | 0.060 |
Why?
|
| Cell Cycle | 5 | 2009 | 2084 | 0.060 |
Why?
|
| Michigan | 1 | 2004 | 67 | 0.060 |
Why?
|
| Radiation, Ionizing | 3 | 2007 | 187 | 0.060 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2000 | 703 | 0.060 |
Why?
|
| Drug Combinations | 5 | 2000 | 621 | 0.060 |
Why?
|
| Ki-67 Antigen | 2 | 2006 | 666 | 0.060 |
Why?
|
| Disease Models, Animal | 4 | 2018 | 7222 | 0.060 |
Why?
|
| Craniopharyngioma | 1 | 1984 | 52 | 0.060 |
Why?
|
| Cisplatin | 3 | 2012 | 2432 | 0.060 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2006 | 2594 | 0.060 |
Why?
|
| Reference Values | 3 | 2004 | 1099 | 0.060 |
Why?
|
| Transcriptome | 1 | 2013 | 1859 | 0.060 |
Why?
|
| Arsenicals | 2 | 2008 | 201 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2005 | 327 | 0.060 |
Why?
|
| Endopeptidases | 4 | 1996 | 220 | 0.060 |
Why?
|
| Telomere | 1 | 2007 | 505 | 0.060 |
Why?
|
| Chemotherapy, Adjuvant | 5 | 2010 | 3890 | 0.060 |
Why?
|
| Loss of Heterozygosity | 1 | 2005 | 602 | 0.060 |
Why?
|
| Multicenter Studies as Topic | 2 | 2022 | 543 | 0.060 |
Why?
|
| Serine Endopeptidases | 2 | 1996 | 275 | 0.060 |
Why?
|
| Amino Acid Sequence | 3 | 1996 | 4233 | 0.060 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2008 | 992 | 0.060 |
Why?
|
| Viruses | 1 | 2005 | 159 | 0.060 |
Why?
|
| Triethylenephosphoramide | 1 | 2003 | 2 | 0.060 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2009 | 5319 | 0.060 |
Why?
|
| Adenocarcinoma | 3 | 1998 | 7789 | 0.060 |
Why?
|
| Specialization | 1 | 2004 | 130 | 0.060 |
Why?
|
| Leukemia | 2 | 2011 | 1635 | 0.060 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 1983 | 68 | 0.060 |
Why?
|
| Cell Death | 1 | 2005 | 671 | 0.060 |
Why?
|
| Plasminogen Inactivators | 2 | 1994 | 9 | 0.060 |
Why?
|
| MAP Kinase Signaling System | 1 | 2007 | 848 | 0.060 |
Why?
|
| Etoposide | 1 | 2005 | 870 | 0.060 |
Why?
|
| Risk Assessment | 1 | 2015 | 6869 | 0.060 |
Why?
|
| beta-Galactosidase | 3 | 1997 | 211 | 0.050 |
Why?
|
| Giant Cell Tumors | 3 | 1998 | 33 | 0.050 |
Why?
|
| Algorithms | 4 | 2006 | 3890 | 0.050 |
Why?
|
| Evoked Potentials, Motor | 2 | 2014 | 58 | 0.050 |
Why?
|
| Cell Proliferation | 5 | 2018 | 7226 | 0.050 |
Why?
|
| Subarachnoid Hemorrhage | 1 | 1983 | 95 | 0.050 |
Why?
|
| Proteins | 3 | 2008 | 1963 | 0.050 |
Why?
|
| Cranial Sinuses | 2 | 2001 | 24 | 0.050 |
Why?
|
| DNA Mutational Analysis | 2 | 2014 | 2283 | 0.050 |
Why?
|
| Medicine | 1 | 2004 | 137 | 0.050 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2003 | 215 | 0.050 |
Why?
|
| Mice, Transgenic | 5 | 2010 | 4143 | 0.050 |
Why?
|
| Urogenital Neoplasms | 3 | 2008 | 108 | 0.050 |
Why?
|
| Peptide Hydrolases | 2 | 1994 | 256 | 0.050 |
Why?
|
| Stem Cells | 2 | 2006 | 1213 | 0.050 |
Why?
|
| Germinoma | 1 | 2002 | 84 | 0.050 |
Why?
|
| Lipoproteins | 1 | 2003 | 252 | 0.050 |
Why?
|
| Dandy-Walker Syndrome | 1 | 1981 | 11 | 0.050 |
Why?
|
| Eye Proteins | 1 | 2003 | 269 | 0.050 |
Why?
|
| Colony-Forming Units Assay | 2 | 2014 | 249 | 0.050 |
Why?
|
| Treatment Failure | 1 | 2005 | 1391 | 0.050 |
Why?
|
| Retreatment | 1 | 2002 | 452 | 0.050 |
Why?
|
| DNA | 2 | 2007 | 2693 | 0.050 |
Why?
|
| Cell Differentiation | 3 | 2010 | 4078 | 0.050 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2005 | 726 | 0.050 |
Why?
|
| Microscopy, Electron | 3 | 2002 | 600 | 0.050 |
Why?
|
| Angiostatins | 1 | 2000 | 7 | 0.050 |
Why?
|
| Mass Screening | 1 | 2009 | 1509 | 0.050 |
Why?
|
| DNA, Neoplasm | 2 | 2001 | 1910 | 0.050 |
Why?
|
| Cyclohexanes | 1 | 2000 | 38 | 0.050 |
Why?
|
| Cerebrospinal Fluid Shunts | 2 | 2017 | 71 | 0.050 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2002 | 726 | 0.050 |
Why?
|
| Bromodeoxyuridine | 3 | 1999 | 139 | 0.050 |
Why?
|
| Extracellular Matrix Proteins | 3 | 1997 | 315 | 0.050 |
Why?
|
| Endostatins | 1 | 2000 | 48 | 0.050 |
Why?
|
| Immunoenzyme Techniques | 6 | 2010 | 1165 | 0.050 |
Why?
|
| Receptor, Adenosine A2A | 1 | 2020 | 27 | 0.050 |
Why?
|
| Nervous System | 1 | 2001 | 165 | 0.050 |
Why?
|
| RNA, Small Interfering | 3 | 2012 | 2216 | 0.050 |
Why?
|
| SEER Program | 1 | 2004 | 1000 | 0.050 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2000 | 66 | 0.050 |
Why?
|
| Regression Analysis | 3 | 2004 | 1546 | 0.050 |
Why?
|
| Population Surveillance | 1 | 2004 | 627 | 0.050 |
Why?
|
| Apyrase | 1 | 2020 | 44 | 0.050 |
Why?
|
| Isoenzymes | 1 | 2003 | 614 | 0.050 |
Why?
|
| Evidence-Based Medicine | 2 | 2009 | 1085 | 0.050 |
Why?
|
| Calcium-Binding Proteins | 1 | 2003 | 545 | 0.050 |
Why?
|
| Sesquiterpenes | 1 | 2000 | 68 | 0.050 |
Why?
|
| Protons | 1 | 2003 | 473 | 0.050 |
Why?
|
| Antigens, Polyomavirus Transforming | 1 | 2000 | 110 | 0.050 |
Why?
|
| Fluorouracil | 1 | 2005 | 1944 | 0.050 |
Why?
|
| 5'-Nucleotidase | 1 | 2020 | 61 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2000 | 212 | 0.050 |
Why?
|
| Research | 3 | 2008 | 415 | 0.050 |
Why?
|
| Receptor, TIE-2 | 1 | 2000 | 82 | 0.050 |
Why?
|
| Gene Expression Regulation | 2 | 2008 | 4053 | 0.050 |
Why?
|
| Vanadates | 1 | 1999 | 21 | 0.050 |
Why?
|
| Stilbenes | 1 | 2000 | 86 | 0.050 |
Why?
|
| Endothelial Growth Factors | 1 | 2000 | 197 | 0.050 |
Why?
|
| Carotid Artery Thrombosis | 1 | 1979 | 11 | 0.050 |
Why?
|
| Retinoids | 1 | 2000 | 164 | 0.040 |
Why?
|
| Lymphokines | 1 | 2000 | 272 | 0.040 |
Why?
|
| Leukapheresis | 1 | 2020 | 152 | 0.040 |
Why?
|
| Carotid Arteries | 1 | 1981 | 240 | 0.040 |
Why?
|
| Gene Knockdown Techniques | 2 | 2013 | 1077 | 0.040 |
Why?
|
| Functional Laterality | 2 | 2017 | 316 | 0.040 |
Why?
|
| Cavernous Sinus | 1 | 1979 | 33 | 0.040 |
Why?
|
| Methotrexate | 1 | 2003 | 999 | 0.040 |
Why?
|
| Down-Regulation | 3 | 2000 | 2074 | 0.040 |
Why?
|
| Financing, Government | 2 | 2009 | 40 | 0.040 |
Why?
|
| Tumor Microenvironment | 2 | 2020 | 2864 | 0.040 |
Why?
|
| Nerve Tissue Proteins | 2 | 2006 | 1491 | 0.040 |
Why?
|
| Furosemide | 1 | 1979 | 41 | 0.040 |
Why?
|
| Research Design | 2 | 2006 | 1544 | 0.040 |
Why?
|
| Matrix Metalloproteinases | 1 | 1999 | 143 | 0.040 |
Why?
|
| Gastrointestinal Neoplasms | 4 | 2008 | 600 | 0.040 |
Why?
|
| Lymphocyte Depletion | 1 | 2020 | 264 | 0.040 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 1999 | 182 | 0.040 |
Why?
|
| Surgical Procedures, Operative | 1 | 2003 | 383 | 0.040 |
Why?
|
| Interferons | 1 | 2000 | 291 | 0.040 |
Why?
|
| Methylmethacrylate | 1 | 1998 | 15 | 0.040 |
Why?
|
| Methylmethacrylates | 1 | 1998 | 16 | 0.040 |
Why?
|
| Cell Nucleus | 3 | 2014 | 1620 | 0.040 |
Why?
|
| Sex Factors | 1 | 2004 | 2139 | 0.040 |
Why?
|
| Arteriovenous Fistula | 1 | 1979 | 92 | 0.040 |
Why?
|
| Bone Plates | 1 | 1998 | 47 | 0.040 |
Why?
|
| Kyphosis | 1 | 1998 | 43 | 0.040 |
Why?
|
| Protein Kinases | 3 | 2007 | 874 | 0.040 |
Why?
|
| Bone Cements | 1 | 1998 | 45 | 0.040 |
Why?
|
| Back Pain | 1 | 1998 | 61 | 0.040 |
Why?
|
| Enzyme Activation | 4 | 2010 | 1764 | 0.040 |
Why?
|
| Pulmonary Atelectasis | 1 | 1998 | 46 | 0.040 |
Why?
|
| Antigens, Neoplasm | 2 | 2003 | 1506 | 0.040 |
Why?
|
| In Situ Hybridization | 3 | 1995 | 1037 | 0.040 |
Why?
|
| Psychometrics | 1 | 2003 | 937 | 0.040 |
Why?
|
| Tumor Escape | 2 | 2010 | 251 | 0.040 |
Why?
|
| Cysteine Endopeptidases | 2 | 1996 | 251 | 0.040 |
Why?
|
| Cell Separation | 2 | 2010 | 612 | 0.040 |
Why?
|
| Membrane Proteins | 2 | 2006 | 2819 | 0.040 |
Why?
|
| Carotid Artery Diseases | 1 | 1979 | 196 | 0.040 |
Why?
|
| Antisense Elements (Genetics) | 1 | 1997 | 18 | 0.040 |
Why?
|
| Muscle Weakness | 1 | 1998 | 116 | 0.040 |
Why?
|
| Fibrin | 4 | 1998 | 82 | 0.040 |
Why?
|
| Community Health Planning | 1 | 2017 | 23 | 0.040 |
Why?
|
| Quality Assurance, Health Care | 1 | 2002 | 585 | 0.040 |
Why?
|
| Craniocerebral Trauma | 1 | 1979 | 130 | 0.040 |
Why?
|
| Cervical Vertebrae | 1 | 1998 | 205 | 0.040 |
Why?
|
| Pyrimidinones | 1 | 2019 | 314 | 0.040 |
Why?
|
| Consensus | 1 | 2021 | 978 | 0.040 |
Why?
|
| Ventriculostomy | 1 | 2017 | 34 | 0.040 |
Why?
|
| Lumbar Vertebrae | 1 | 1998 | 245 | 0.040 |
Why?
|
| Giant Cell Tumor of Bone | 1 | 1997 | 52 | 0.040 |
Why?
|
| Immunoprecipitation | 2 | 2009 | 591 | 0.040 |
Why?
|
| Radiotherapy Dosage | 3 | 2005 | 3842 | 0.040 |
Why?
|
| Catheterization | 1 | 1979 | 410 | 0.040 |
Why?
|
| Thalidomide | 1 | 2000 | 569 | 0.040 |
Why?
|
| Repressor Proteins | 1 | 2005 | 1664 | 0.040 |
Why?
|
| Edetic Acid | 2 | 1995 | 73 | 0.040 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 2 | 2007 | 131 | 0.040 |
Why?
|
| Pyridones | 1 | 2019 | 348 | 0.040 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 1998 | 209 | 0.040 |
Why?
|
| Fibroblast Growth Factor 2 | 2 | 2008 | 223 | 0.040 |
Why?
|
| Pain, Intractable | 1 | 1998 | 171 | 0.040 |
Why?
|
| Gait Disorders, Neurologic | 1 | 2017 | 58 | 0.040 |
Why?
|
| Spectrometry, Fluorescence | 1 | 1997 | 209 | 0.040 |
Why?
|
| Speech Disorders | 1 | 2017 | 91 | 0.040 |
Why?
|
| Case Management | 1 | 1996 | 35 | 0.040 |
Why?
|
| ROC Curve | 2 | 2014 | 1183 | 0.040 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 1996 | 94 | 0.040 |
Why?
|
| Cathepsin D | 1 | 1996 | 32 | 0.040 |
Why?
|
| Cytarabine | 1 | 2003 | 1973 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 4 | 1994 | 4367 | 0.040 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2000 | 661 | 0.040 |
Why?
|
| Single-Blind Method | 1 | 2017 | 409 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 3 | 1997 | 2063 | 0.030 |
Why?
|
| Hyaluronic Acid | 2 | 1996 | 168 | 0.030 |
Why?
|
| Observer Variation | 1 | 1998 | 671 | 0.030 |
Why?
|
| Tissue Distribution | 2 | 1995 | 875 | 0.030 |
Why?
|
| TOR Serine-Threonine Kinases | 3 | 2007 | 1546 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 4 | 2008 | 3203 | 0.030 |
Why?
|
| Walking | 1 | 1998 | 277 | 0.030 |
Why?
|
| Genital Neoplasms, Female | 3 | 2008 | 735 | 0.030 |
Why?
|
| Therapy, Computer-Assisted | 1 | 1996 | 61 | 0.030 |
Why?
|
| Intraoperative Period | 1 | 1996 | 246 | 0.030 |
Why?
|
| Cyclin D1 | 2 | 2010 | 576 | 0.030 |
Why?
|
| Healthy Volunteers | 1 | 2016 | 187 | 0.030 |
Why?
|
| Receptors, Lymphocyte Homing | 1 | 1995 | 25 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2002 | 2803 | 0.030 |
Why?
|
| X-linked Nuclear Protein | 1 | 2015 | 56 | 0.030 |
Why?
|
| T-Lymphocyte Subsets | 2 | 2009 | 582 | 0.030 |
Why?
|
| Antigens, CD | 1 | 2020 | 1385 | 0.030 |
Why?
|
| Transplantation, Autologous | 1 | 2020 | 1914 | 0.030 |
Why?
|
| Glial Fibrillary Acidic Protein | 3 | 2006 | 151 | 0.030 |
Why?
|
| Cathepsin B | 1 | 1995 | 32 | 0.030 |
Why?
|
| Metastasectomy | 1 | 2017 | 200 | 0.030 |
Why?
|
| Quality of Life | 3 | 2009 | 4532 | 0.030 |
Why?
|
| Oligonucleotide Probes | 1 | 1995 | 130 | 0.030 |
Why?
|
| Surgical Instruments | 1 | 1995 | 138 | 0.030 |
Why?
|
| Cranial Fossa, Posterior | 2 | 2008 | 49 | 0.030 |
Why?
|
| Receptors, Fibronectin | 2 | 1996 | 25 | 0.030 |
Why?
|
| Cytotoxicity Tests, Immunologic | 1 | 2014 | 84 | 0.030 |
Why?
|
| Fibrinogen | 2 | 1986 | 205 | 0.030 |
Why?
|
| Lymphocyte Activation | 2 | 2010 | 1688 | 0.030 |
Why?
|
| Peptide Fragments | 1 | 2000 | 1271 | 0.030 |
Why?
|
| Pain Measurement | 1 | 1998 | 953 | 0.030 |
Why?
|
| DNA Primers | 2 | 2008 | 1399 | 0.030 |
Why?
|
| Mutism | 1 | 1994 | 21 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2016 | 700 | 0.030 |
Why?
|
| Oxyhemoglobins | 1 | 2004 | 25 | 0.030 |
Why?
|
| Intracellular Fluid | 1 | 1994 | 45 | 0.030 |
Why?
|
| Anatomy, Artistic | 1 | 2014 | 10 | 0.030 |
Why?
|
| Protease Nexins | 1 | 1993 | 7 | 0.030 |
Why?
|
| Coculture Techniques | 3 | 2000 | 626 | 0.030 |
Why?
|
| Protein Array Analysis | 2 | 2007 | 501 | 0.030 |
Why?
|
| Skin | 1 | 1999 | 1259 | 0.030 |
Why?
|
| bcl-2-Associated X Protein | 2 | 2006 | 367 | 0.030 |
Why?
|
| Cell Lineage | 2 | 2011 | 668 | 0.030 |
Why?
|
| Extracellular Space | 1 | 1994 | 132 | 0.030 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2020 | 1048 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2015 | 272 | 0.030 |
Why?
|
| Serine Proteinase Inhibitors | 1 | 1994 | 60 | 0.030 |
Why?
|
| NIH 3T3 Cells | 1 | 2014 | 260 | 0.030 |
Why?
|
| Endoscopes | 1 | 1993 | 43 | 0.030 |
Why?
|
| Frontal Lobe | 1 | 1994 | 187 | 0.030 |
Why?
|
| Stromal Cells | 1 | 1997 | 825 | 0.030 |
Why?
|
| Cytokines | 2 | 2014 | 2809 | 0.030 |
Why?
|
| Neurilemmoma | 1 | 1994 | 127 | 0.030 |
Why?
|
| Lead | 1 | 1993 | 54 | 0.030 |
Why?
|
| DNA Helicases | 1 | 2015 | 434 | 0.030 |
Why?
|
| Fibroblasts | 2 | 2012 | 1682 | 0.030 |
Why?
|
| G2 Phase Cell Cycle Checkpoints | 1 | 2012 | 76 | 0.030 |
Why?
|
| Amyloid beta-Protein Precursor | 1 | 1993 | 137 | 0.030 |
Why?
|
| Heat Shock Transcription Factors | 1 | 2012 | 51 | 0.030 |
Why?
|
| Tissue Array Analysis | 1 | 2014 | 760 | 0.030 |
Why?
|
| Case-Control Studies | 2 | 2002 | 6100 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 2013 | 108 | 0.030 |
Why?
|
| Biocompatible Materials | 1 | 1994 | 202 | 0.030 |
Why?
|
| Forecasting | 1 | 1995 | 694 | 0.030 |
Why?
|
| Biopsy, Needle | 1 | 1997 | 1363 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2001 | 4971 | 0.030 |
Why?
|
| Oxygen Consumption | 1 | 2004 | 401 | 0.030 |
Why?
|
| Analysis of Variance | 2 | 2009 | 2307 | 0.030 |
Why?
|
| Meninges | 1 | 1992 | 47 | 0.030 |
Why?
|
| Carboplatin | 1 | 1995 | 823 | 0.030 |
Why?
|
| Retina | 1 | 1996 | 532 | 0.030 |
Why?
|
| PTEN Phosphohydrolase | 2 | 2010 | 986 | 0.030 |
Why?
|
| Protein Binding | 2 | 2012 | 3438 | 0.030 |
Why?
|
| Aurora Kinases | 1 | 2012 | 189 | 0.030 |
Why?
|
| Tandem Repeat Sequences | 1 | 2013 | 201 | 0.030 |
Why?
|
| Stomach Neoplasms | 1 | 2005 | 2278 | 0.030 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2014 | 303 | 0.030 |
Why?
|
| Hemoglobins | 1 | 2004 | 477 | 0.030 |
Why?
|
| Alternative Splicing | 1 | 1995 | 584 | 0.030 |
Why?
|
| Ubiquitin | 1 | 2014 | 344 | 0.030 |
Why?
|
| Hot Temperature | 1 | 2012 | 281 | 0.030 |
Why?
|
| Neck | 1 | 1994 | 383 | 0.030 |
Why?
|
| 3' Untranslated Regions | 1 | 2013 | 343 | 0.030 |
Why?
|
| Length of Stay | 1 | 1998 | 1900 | 0.020 |
Why?
|
| Aurora Kinase A | 1 | 2012 | 202 | 0.020 |
Why?
|
| Protein C | 1 | 1991 | 32 | 0.020 |
Why?
|
| Glycoproteins | 1 | 1995 | 747 | 0.020 |
Why?
|
| Electroencephalography | 1 | 1995 | 898 | 0.020 |
Why?
|
| Models, Biological | 2 | 2005 | 3254 | 0.020 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2004 | 500 | 0.020 |
Why?
|
| Phosphopeptides | 1 | 2011 | 65 | 0.020 |
Why?
|
| Injections, Intradermal | 1 | 2010 | 58 | 0.020 |
Why?
|
| Motor Skills Disorders | 1 | 2010 | 20 | 0.020 |
Why?
|
| Hypersensitivity, Delayed | 1 | 2010 | 104 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2008 | 1062 | 0.020 |
Why?
|
| Glasgow Coma Scale | 1 | 2011 | 215 | 0.020 |
Why?
|
| Chemotactic Factors | 1 | 2010 | 42 | 0.020 |
Why?
|
| Factor Xa | 1 | 2010 | 26 | 0.020 |
Why?
|
| Platelet Transfusion | 1 | 2011 | 156 | 0.020 |
Why?
|
| Scalp | 1 | 1992 | 156 | 0.020 |
Why?
|
| HL-60 Cells | 1 | 2011 | 302 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2016 | 2292 | 0.020 |
Why?
|
| Cdc20 Proteins | 1 | 2010 | 25 | 0.020 |
Why?
|
| Cyclin B1 | 1 | 2010 | 56 | 0.020 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 2011 | 187 | 0.020 |
Why?
|
| Nedd4 Ubiquitin Protein Ligases | 1 | 2010 | 23 | 0.020 |
Why?
|
| Genes, bcl-2 | 1 | 2010 | 166 | 0.020 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2010 | 157 | 0.020 |
Why?
|
| DNA Modification Methylases | 1 | 2010 | 172 | 0.020 |
Why?
|
| Sample Size | 1 | 2010 | 202 | 0.020 |
Why?
|
| Oncogene Protein v-akt | 1 | 2010 | 101 | 0.020 |
Why?
|
| Mexico | 1 | 2010 | 259 | 0.020 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2010 | 1823 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2013 | 837 | 0.020 |
Why?
|
| Nuclear Proteins | 2 | 2015 | 3343 | 0.020 |
Why?
|
| Motor Activity | 1 | 1994 | 693 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-sis | 1 | 2009 | 80 | 0.020 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1990 | 354 | 0.020 |
Why?
|
| Equipment Design | 1 | 1993 | 1204 | 0.020 |
Why?
|
| Placebos | 1 | 2010 | 437 | 0.020 |
Why?
|
| Embryo, Mammalian | 1 | 2012 | 741 | 0.020 |
Why?
|
| src-Family Kinases | 1 | 2012 | 478 | 0.020 |
Why?
|
| Ultrasonography | 1 | 1996 | 1863 | 0.020 |
Why?
|
| Mitochondria | 2 | 2007 | 1282 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2014 | 1489 | 0.020 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2010 | 202 | 0.020 |
Why?
|
| DNA Repair Enzymes | 1 | 2010 | 237 | 0.020 |
Why?
|
| Suppressor of Cytokine Signaling 1 Protein | 1 | 2008 | 18 | 0.020 |
Why?
|
| Factor VIII | 2 | 1986 | 75 | 0.020 |
Why?
|
| Sequence Deletion | 1 | 2012 | 875 | 0.020 |
Why?
|
| Protein Stability | 1 | 2010 | 370 | 0.020 |
Why?
|
| Research Support as Topic | 1 | 2009 | 122 | 0.020 |
Why?
|
| Phenotype | 2 | 2011 | 6295 | 0.020 |
Why?
|
| Tetradecanoylphorbol Acetate | 2 | 1999 | 226 | 0.020 |
Why?
|
| Colorectal Neoplasms | 1 | 2004 | 3578 | 0.020 |
Why?
|
| Drug Administration Schedule | 2 | 2010 | 3472 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 3251 | 0.020 |
Why?
|
| Genes | 1 | 1990 | 491 | 0.020 |
Why?
|
| Diagnostic Imaging | 1 | 1997 | 1162 | 0.020 |
Why?
|
| Analgesics, Opioid | 1 | 1998 | 1371 | 0.020 |
Why?
|
| Neurologic Examination | 1 | 2009 | 245 | 0.020 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2014 | 925 | 0.020 |
Why?
|
| Molecular Structure | 1 | 1990 | 515 | 0.020 |
Why?
|
| Organ Specificity | 1 | 2010 | 699 | 0.020 |
Why?
|
| Focal Adhesion Kinase 1 | 2 | 1999 | 111 | 0.020 |
Why?
|
| NF-KappaB Inhibitor alpha | 1 | 2008 | 136 | 0.020 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2011 | 368 | 0.020 |
Why?
|
| Recurrence | 1 | 1997 | 4758 | 0.020 |
Why?
|
| Chemokines | 1 | 2010 | 314 | 0.020 |
Why?
|
| Interleukin-10 | 1 | 2011 | 478 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2015 | 2218 | 0.020 |
Why?
|
| Bayes Theorem | 1 | 2013 | 1021 | 0.020 |
Why?
|
| DNA, Complementary | 2 | 2000 | 869 | 0.020 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 2 | 1999 | 161 | 0.020 |
Why?
|
| Patient Acceptance of Health Care | 1 | 1993 | 573 | 0.020 |
Why?
|
| Receptors, Immunologic | 1 | 1990 | 309 | 0.020 |
Why?
|
| Phagosomes | 1 | 2008 | 72 | 0.020 |
Why?
|
| Procarbazine | 2 | 1999 | 69 | 0.020 |
Why?
|
| Tubulin Modulators | 1 | 2008 | 65 | 0.020 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2008 | 212 | 0.020 |
Why?
|
| Lomustine | 2 | 1999 | 39 | 0.020 |
Why?
|
| Pons | 1 | 2008 | 51 | 0.020 |
Why?
|
| Cyclin E | 1 | 2010 | 267 | 0.020 |
Why?
|
| I-kappa B Proteins | 1 | 2008 | 170 | 0.020 |
Why?
|
| RNA Interference | 1 | 2012 | 1408 | 0.020 |
Why?
|
| Ceramides | 1 | 2008 | 95 | 0.020 |
Why?
|
| Culture Media, Serum-Free | 2 | 1997 | 74 | 0.020 |
Why?
|
| Cauda Equina | 1 | 1987 | 12 | 0.020 |
Why?
|
| Protein-Tyrosine Kinases | 3 | 2000 | 1756 | 0.020 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2013 | 755 | 0.020 |
Why?
|
| Nerve Compression Syndromes | 1 | 1987 | 30 | 0.020 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2008 | 611 | 0.020 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2008 | 518 | 0.020 |
Why?
|
| Ligation | 1 | 1987 | 193 | 0.020 |
Why?
|
| Head and Neck Neoplasms | 3 | 2007 | 3976 | 0.020 |
Why?
|
| Oxides | 1 | 2008 | 211 | 0.020 |
Why?
|
| Immunologic Factors | 1 | 2011 | 649 | 0.020 |
Why?
|
| Cattle | 2 | 2000 | 783 | 0.020 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2007 | 133 | 0.020 |
Why?
|
| Gelatin | 2 | 1997 | 49 | 0.020 |
Why?
|
| Chordoma | 2 | 1998 | 163 | 0.020 |
Why?
|
| Venous Thrombosis | 1 | 2010 | 384 | 0.020 |
Why?
|
| DNA Replication | 1 | 1991 | 744 | 0.020 |
Why?
|
| Antineoplastic Protocols | 1 | 2006 | 33 | 0.020 |
Why?
|
| Health Policy | 1 | 2009 | 291 | 0.020 |
Why?
|
| G2 Phase | 1 | 2007 | 206 | 0.020 |
Why?
|
| Superior Colliculi | 1 | 1986 | 18 | 0.020 |
Why?
|
| Cellulose, Oxidized | 1 | 1986 | 6 | 0.020 |
Why?
|
| Chitin | 1 | 1986 | 5 | 0.020 |
Why?
|
| Chondrosarcoma | 2 | 1998 | 216 | 0.020 |
Why?
|
| Gelatin Sponge, Absorbable | 1 | 1986 | 9 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2014 | 4938 | 0.020 |
Why?
|
| Anthracenes | 1 | 2006 | 48 | 0.020 |
Why?
|
| S-Phase Kinase-Associated Proteins | 1 | 2006 | 51 | 0.020 |
Why?
|
| Aprotinin | 1 | 1986 | 34 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2009 | 1323 | 0.020 |
Why?
|
| Protease Inhibitors | 1 | 1987 | 210 | 0.020 |
Why?
|
| Spheroids, Cellular | 2 | 1997 | 222 | 0.020 |
Why?
|
| Blood Proteins | 1 | 1987 | 294 | 0.020 |
Why?
|
| Immunity, Innate | 1 | 2010 | 677 | 0.020 |
Why?
|
| Interleukin-8 | 1 | 2008 | 519 | 0.020 |
Why?
|
| Cerebellar Diseases | 1 | 1986 | 89 | 0.020 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-2 | 2 | 1996 | 19 | 0.020 |
Why?
|
| Electric Stimulation Therapy | 1 | 1986 | 116 | 0.020 |
Why?
|
| Dexamethasone | 2 | 1988 | 1450 | 0.020 |
Why?
|
| Hormone Replacement Therapy | 1 | 2007 | 205 | 0.020 |
Why?
|
| Thrombin | 1 | 1986 | 99 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 2008 | 702 | 0.020 |
Why?
|
| Chitosan | 1 | 1986 | 79 | 0.020 |
Why?
|
| Cytoplasm | 1 | 2007 | 652 | 0.020 |
Why?
|
| Flucytosine | 1 | 2005 | 30 | 0.020 |
Why?
|
| Hematoma | 1 | 1986 | 160 | 0.020 |
Why?
|
| Decerebrate State | 1 | 1985 | 2 | 0.020 |
Why?
|
| Chromatography, Thin Layer | 1 | 2005 | 70 | 0.020 |
Why?
|
| Poly-ADP-Ribose Binding Proteins | 1 | 2005 | 109 | 0.020 |
Why?
|
| Hemostatics | 1 | 1986 | 88 | 0.020 |
Why?
|
| Sinus Thrombosis, Intracranial | 1 | 1985 | 42 | 0.020 |
Why?
|
| Inappropriate ADH Syndrome | 1 | 1985 | 11 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2006 | 287 | 0.020 |
Why?
|
| Vimentin | 1 | 2006 | 253 | 0.020 |
Why?
|
| DNA-Activated Protein Kinase | 1 | 2005 | 76 | 0.020 |
Why?
|
| Thrombophlebitis | 1 | 1984 | 31 | 0.020 |
Why?
|
| Quality of Health Care | 1 | 2009 | 621 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2005 | 342 | 0.020 |
Why?
|
| Anticoagulants | 1 | 2010 | 787 | 0.020 |
Why?
|
| Hematologic Neoplasms | 2 | 2006 | 1870 | 0.020 |
Why?
|
| Glomus Jugulare Tumor | 1 | 1984 | 8 | 0.020 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2005 | 289 | 0.020 |
Why?
|
| Prostheses and Implants | 1 | 1986 | 295 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2009 | 1033 | 0.020 |
Why?
|
| Janus Kinase 2 | 1 | 2008 | 679 | 0.020 |
Why?
|
| Hematoma, Subdural | 1 | 1984 | 28 | 0.020 |
Why?
|
| Adenovirus E1A Proteins | 1 | 2005 | 163 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2006 | 482 | 0.020 |
Why?
|
| Microsatellite Repeats | 1 | 2006 | 575 | 0.020 |
Why?
|
| Central Nervous System Diseases | 1 | 1985 | 129 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2010 | 1265 | 0.020 |
Why?
|
| Protein Subunits | 1 | 2005 | 274 | 0.020 |
Why?
|
| Catalytic Domain | 1 | 2005 | 303 | 0.010 |
Why?
|
| Multiple Myeloma | 1 | 1995 | 2138 | 0.010 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2008 | 803 | 0.010 |
Why?
|
| Genetic Heterogeneity | 1 | 2005 | 318 | 0.010 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2005 | 243 | 0.010 |
Why?
|
| Actuarial Analysis | 1 | 2003 | 159 | 0.010 |
Why?
|
| Hippocalcin | 1 | 2003 | 13 | 0.010 |
Why?
|
| Trypan Blue | 1 | 2003 | 14 | 0.010 |
Why?
|
| Recoverin | 1 | 2003 | 22 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 2006 | 842 | 0.010 |
Why?
|
| Neuroblastoma | 1 | 1989 | 686 | 0.010 |
Why?
|
| Vincristine | 2 | 1999 | 1511 | 0.010 |
Why?
|
| Antigens, CD34 | 1 | 2005 | 593 | 0.010 |
Why?
|
| Brain Stem | 1 | 1984 | 175 | 0.010 |
Why?
|
| Brain Concussion | 1 | 1985 | 194 | 0.010 |
Why?
|
| Green Fluorescent Proteins | 1 | 2005 | 694 | 0.010 |
Why?
|
| Creatine | 1 | 2002 | 61 | 0.010 |
Why?
|
| HeLa Cells | 1 | 2006 | 1643 | 0.010 |
Why?
|
| Coloring Agents | 1 | 2003 | 234 | 0.010 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 1998 | 5437 | 0.010 |
Why?
|
| Choline | 1 | 2002 | 76 | 0.010 |
Why?
|
| Bone and Bones | 1 | 1986 | 619 | 0.010 |
Why?
|
| Drug Evaluation | 1 | 2002 | 425 | 0.010 |
Why?
|
| Antifibrinolytic Agents | 1 | 1983 | 68 | 0.010 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2006 | 622 | 0.010 |
Why?
|
| Anemia, Sideroblastic | 1 | 1982 | 58 | 0.010 |
Why?
|
| Cerebral Ventriculography | 1 | 1981 | 2 | 0.010 |
Why?
|
| Laser Therapy | 1 | 1986 | 411 | 0.010 |
Why?
|
| Ependymoma | 1 | 1984 | 242 | 0.010 |
Why?
|
| Spinal Diseases | 1 | 1982 | 125 | 0.010 |
Why?
|
| Sex Distribution | 1 | 2003 | 495 | 0.010 |
Why?
|
| Agenesis of Corpus Callosum | 1 | 1981 | 36 | 0.010 |
Why?
|
| Retinoblastoma | 1 | 2003 | 200 | 0.010 |
Why?
|
| Hemangiosarcoma | 1 | 1984 | 234 | 0.010 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2011 | 2370 | 0.010 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2005 | 621 | 0.010 |
Why?
|
| Cell Cycle Proteins | 1 | 2010 | 2045 | 0.010 |
Why?
|
| Spinal Cord Compression | 1 | 1982 | 151 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2003 | 980 | 0.010 |
Why?
|
| Gene Deletion | 1 | 2006 | 1442 | 0.010 |
Why?
|
| Lactic Acid | 1 | 2002 | 305 | 0.010 |
Why?
|
| Paclitaxel | 1 | 2008 | 1996 | 0.010 |
Why?
|
| Intelligence | 1 | 1981 | 126 | 0.010 |
Why?
|
| Fluorescent Dyes | 1 | 2003 | 459 | 0.010 |
Why?
|
| Cognition Disorders | 1 | 2006 | 786 | 0.010 |
Why?
|
| Cyclooxygenase 2 | 1 | 2003 | 483 | 0.010 |
Why?
|
| Models, Animal | 1 | 2002 | 664 | 0.010 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2000 | 448 | 0.010 |
Why?
|
| Cell Line, Transformed | 1 | 2000 | 394 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2009 | 5710 | 0.010 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2002 | 665 | 0.010 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2002 | 604 | 0.010 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2006 | 1678 | 0.010 |
Why?
|
| Specific Gravity | 1 | 1979 | 8 | 0.010 |
Why?
|
| Carotid Artery, Internal | 1 | 1979 | 77 | 0.010 |
Why?
|
| Contusions | 1 | 1979 | 18 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2009 | 2403 | 0.010 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2003 | 551 | 0.010 |
Why?
|
| Blood Urea Nitrogen | 1 | 1979 | 95 | 0.010 |
Why?
|
| Lipid Metabolism | 1 | 2002 | 483 | 0.010 |
Why?
|
| RNA, Antisense | 1 | 1999 | 69 | 0.010 |
Why?
|
| Drinking | 1 | 1979 | 54 | 0.010 |
Why?
|
| Cats | 1 | 1979 | 166 | 0.010 |
Why?
|
| Cytochalasin D | 1 | 1998 | 19 | 0.010 |
Why?
|
| Plasmids | 1 | 2000 | 837 | 0.010 |
Why?
|
| Diagnostic Errors | 1 | 2003 | 509 | 0.010 |
Why?
|
| Biopolymers | 1 | 1998 | 38 | 0.010 |
Why?
|
| Neovascularization, Physiologic | 1 | 2000 | 345 | 0.010 |
Why?
|
| Iatrogenic Disease | 1 | 1979 | 183 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 3639 | 0.010 |
Why?
|
| Microscopy, Confocal | 1 | 2000 | 663 | 0.010 |
Why?
|
| Enzyme Induction | 1 | 1998 | 249 | 0.010 |
Why?
|
| Densitometry | 1 | 1997 | 45 | 0.010 |
Why?
|
| Potassium | 1 | 1979 | 329 | 0.010 |
Why?
|
| Carcinogenicity Tests | 1 | 1997 | 70 | 0.010 |
Why?
|
| Cell Line | 2 | 2000 | 5114 | 0.010 |
Why?
|
| Sodium | 1 | 1979 | 353 | 0.010 |
Why?
|
| DNA Repair | 1 | 2005 | 1872 | 0.010 |
Why?
|
| DNA Damage | 1 | 2005 | 1954 | 0.010 |
Why?
|
| Culture Media, Conditioned | 1 | 1997 | 260 | 0.010 |
Why?
|
| Cathepsin H | 1 | 1996 | 2 | 0.010 |
Why?
|
| Organoids | 1 | 1999 | 287 | 0.010 |
Why?
|
| Integrin alpha3beta1 | 1 | 1996 | 5 | 0.010 |
Why?
|
| Histocytochemistry | 2 | 1987 | 185 | 0.010 |
Why?
|
| Fluorescence | 1 | 1997 | 195 | 0.010 |
Why?
|
| Matrix Metalloproteinases, Membrane-Associated | 1 | 1996 | 7 | 0.010 |
Why?
|
| Lasers | 1 | 1997 | 198 | 0.010 |
Why?
|
| Protein Kinase C | 1 | 1998 | 396 | 0.010 |
Why?
|
| Cathepsin L | 1 | 1996 | 25 | 0.010 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 1996 | 189 | 0.010 |
Why?
|
| Concanavalin A | 1 | 1996 | 67 | 0.010 |
Why?
|
| Enzyme Precursors | 1 | 1996 | 66 | 0.010 |
Why?
|
| Retinoblastoma Protein | 1 | 1997 | 335 | 0.010 |
Why?
|
| Chemotaxis | 1 | 1996 | 138 | 0.010 |
Why?
|
| Staining and Labeling | 1 | 1997 | 429 | 0.010 |
Why?
|
| Salvage Therapy | 1 | 2004 | 2054 | 0.010 |
Why?
|
| Clone Cells | 1 | 1997 | 555 | 0.010 |
Why?
|
| Microcirculation | 1 | 1996 | 200 | 0.010 |
Why?
|
| Substrate Specificity | 1 | 1996 | 549 | 0.010 |
Why?
|
| Biological Assay | 1 | 1996 | 177 | 0.010 |
Why?
|
| Chelating Agents | 1 | 1995 | 127 | 0.010 |
Why?
|
| Tissue Inhibitor of Metalloproteinases | 1 | 1995 | 43 | 0.010 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2006 | 1833 | 0.010 |
Why?
|
| Morphogenesis | 1 | 1996 | 337 | 0.010 |
Why?
|
| Genes, Reporter | 1 | 1996 | 798 | 0.010 |
Why?
|
| Primary Myelofibrosis | 1 | 1982 | 831 | 0.010 |
Why?
|
| Binding Sites | 1 | 1998 | 2171 | 0.010 |
Why?
|
| Hyaluronan Receptors | 1 | 1995 | 249 | 0.010 |
Why?
|
| Mitotic Index | 1 | 1994 | 162 | 0.010 |
Why?
|
| Body Weight | 1 | 1979 | 1293 | 0.010 |
Why?
|
| Disease | 1 | 1995 | 165 | 0.010 |
Why?
|
| Neoplasms, Experimental | 1 | 1997 | 750 | 0.010 |
Why?
|
| Lymphatic Metastasis | 1 | 2003 | 4844 | 0.010 |
Why?
|
| Cognition | 1 | 1999 | 968 | 0.010 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 1999 | 1299 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 1997 | 2927 | 0.010 |
Why?
|
| Idoxuridine | 1 | 1991 | 17 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 1994 | 1382 | 0.010 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 1997 | 1331 | 0.010 |
Why?
|
| S Phase | 1 | 1991 | 281 | 0.010 |
Why?
|
| Cause of Death | 1 | 1993 | 752 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 1981 | 8223 | 0.000 |
Why?
|
| Myelography | 1 | 1987 | 16 | 0.000 |
Why?
|
| Colonic Neoplasms | 1 | 1995 | 1390 | 0.000 |
Why?
|
| Rats, Inbred Strains | 1 | 1986 | 410 | 0.000 |
Why?
|
| Leukemia, Myeloid | 1 | 1991 | 941 | 0.000 |
Why?
|
| Liver Neoplasms | 1 | 2003 | 4557 | 0.000 |
Why?
|
| Subtraction Technique | 1 | 1985 | 141 | 0.000 |
Why?
|
| Epidural Space | 1 | 1982 | 42 | 0.000 |
Why?
|
| Laminectomy | 1 | 1982 | 52 | 0.000 |
Why?
|
| Acute Disease | 1 | 1984 | 2422 | 0.000 |
Why?
|
| Epilepsy | 1 | 1986 | 883 | 0.000 |
Why?
|
| Brain Injuries | 1 | 1985 | 787 | 0.000 |
Why?
|
| Inflammation | 1 | 1986 | 2522 | 0.000 |
Why?
|